Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
المؤلف | Nasrallah, Gheyath K |
المؤلف | Dargham, Soha R |
المؤلف | Shurrab, Farah |
المؤلف | Al-Sadeq, Duaa W |
المؤلف | Al-Jighefee, Hadeel |
المؤلف | Chemaitelly, Hiam |
المؤلف | Al Kanaani, Zaina |
المؤلف | Al Khal, Abdullatif |
المؤلف | Al Kuwari, Einas |
المؤلف | Coyle, Peter |
المؤلف | Jeremijenko, Andrew |
المؤلف | Kaleeckal, Anvar Hassan |
المؤلف | Latif, Ali Nizar |
المؤلف | Shaik, Riyazuddin Mohammad |
المؤلف | Rahim, Hanan F Abdul |
المؤلف | Yassine, Hadi M |
المؤلف | Al Kuwari, Mohamed G |
المؤلف | Qotba, Hamda |
المؤلف | Al Romaihi, Hamad Eid |
المؤلف | Tang, Patrick |
المؤلف | Bertollini, Roberto |
المؤلف | Al-Thani, Mohamed H |
المؤلف | Althani, Asmaa A |
المؤلف | Abu-Raddad, Laith J |
تاريخ الإتاحة | 2021-06-08T09:19:34Z |
تاريخ النشر | 2021-06-01 |
اسم المنشور | scientific reports |
المعرّف | http://dx.doi.org/10.1038/s41598-021-91235-x |
الاقتباس | Nasrallah, G.K., Dargham, S.R., Shurrab, F. et al. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep 11, 11837 (2021). https://doi.org/10.1038/s41598-021-91235-x |
الرقم المعياري الدولي للكتاب | 2045-2322 |
الملخص | Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological testing was performed on 394 individuals. SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1-47.8%), 40.6% (95% CI 35.9-45.5%), and 42.4% (95% CI 37.6-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2-95.7%, 89.3-92.8%, and 93.8-97.8%, respectively; Cohen's kappa statistic ranged from 0.86 to 0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively. All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high. |
اللغة | en |
الناشر | Nature Research |
الموضوع | SARS‑CoV‑2 antibody assays |
النوع | Article |
الملفات في هذه التسجيلة
هذه التسجيلة تظهر في المجموعات التالية
-
الأبحاث [709 items ]
-
العلوم الحيوية الطبية [692 items ]
-
أبحاث فيروس كورونا المستجد (كوفيد-19) [799 items ]